Susan M O'Brien

Title(s)Professor, Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-7511
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 Jun 17. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. PMID: 34138471.
      View in: PubMed   Mentions:    Fields:    
    2. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021 Apr 27. Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP. PMID: 33907299.
      View in: PubMed   Mentions:    Fields:    
    3. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 May 15; 27(10):2742-2754. Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Stelljes M, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS. PMID: 33602684.
      View in: PubMed   Mentions: 2     Fields:    
    4. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. PMID: 32955970.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Highlights in chronic lymphocytic leukemia from the 2020 American Society of Clinical Oncology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2020 Sep; 18 Suppl 13(9):13-17. O'Brien SM. PMID: 33843885.
      View in: PubMed   Mentions:    Fields:    
    6. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. PMID: 32589978.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    7. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020 Apr; 16(10):517-523. Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, Salmi T, Hilger J, Wu K, Cohen A, Huang J, Tam CS. PMID: 32207333.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    8. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. PMID: 31537528.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    9. Highlights from the XVIII International Workshop on Chronic Lymphocytic Leukemia: commentary. Clin Adv Hematol Oncol. 2019 Nov; 17 Suppl 16(11):24-27. O'Brien SM. PMID: 33843854.
      View in: PubMed   Mentions:    Fields:    
    10. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2020 01; 34(1):296-300. Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E, Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O'Brien SM, Pettitt AR, Hallek M. PMID: 31427720.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    11. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. PMID: 31447270.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    12. Highlights in Chronic Lymphocytic Leukemia From the 2019 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2019 Jul; 17 Suppl 11(7):24-27. O'Brien SM. PMID: 32720930.
      View in: PubMed   Mentions:    Fields:    
    13. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. PMID: 31196847.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    14. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. PMID: 31076409.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. PMID: 30995176.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    16. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. PMID: 30985931.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    17. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487. Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS. PMID: 30920645.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    18. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. PMID: 30767298.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    19. Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2019 01; 17 Suppl 1(1):20-23. O'Brien SM. PMID: 31545308.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. PMID: 30506764.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    21. Clinical implications of the 2018 iwCLL Guidelines update. Clin Adv Hematol Oncol. 2018 Aug; 16 Suppl 15(8):1-16. O'Brien SM. PMID: 30300339.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2018 Jul; 16 Suppl 12(7):14-15. O'Brien SM. PMID: 30235180.
      View in: PubMed   Mentions: 1     Fields:    
    23. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):648-657.e15. O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. PMID: 30061088.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    24. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018 08; 182(4):504-512. Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM. PMID: 29873072.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    25. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 05 01; 4(5):712-716. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. PMID: 29470582.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    26. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. PMID: 29769624.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    27. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. PMID: 29645075.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    28. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. PMID: 29479067.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Rituximab maintenance is efficacious, but is it useful? Lancet Haematol. 2018 02; 5(2):e58-e59. O'Brien S. PMID: 29406147.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2018 Jan; 16 Suppl 2(1):16-19. O'Brien SM. PMID: 29742092.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. PMID: 28798068.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    32. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. PMID: 28718728.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    33. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. PMID: 28708931.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    34. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398. Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI. PMID: 28687420.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    35. Highlights From the XVII International Workshop on Chronic Lymphocytic Leukemia: Commentary. Clin Adv Hematol Oncol. 2017 Jul; 15 Suppl 6(7):13-15. O'Brien SM. PMID: 28837123.
      View in: PubMed   Mentions:    Fields:    
    36. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. PMID: 28295472.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    37. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. PMID: 28397242.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    38. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. PMID: 27655665.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    39. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403. Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM. PMID: 28328172.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    40. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. PMID: 28295181.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    41. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. PMID: 28006851.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    42. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv. 2016 Dec 27; 1(3):250-259. Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR. PMID: 29046900.
      View in: PubMed   Mentions: 21     Fields:    
    43. Considerations in the frontline treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2016 Dec; 14(12):970-973. O'Brien SM. PMID: 28212359.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10; 35(2):166-174. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. PMID: 27870563.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    45. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. PMID: 27763690.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. PMID: 27696391.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    47. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. PMID: 27637985.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCellsCTClinical Trials
    48. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. PMID: 27602508.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    49. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. PMID: 27508525.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    50. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. PMID: 27479888.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    51. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. PMID: 27178680.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    52. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. PMID: 27235138.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    53. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 08 15; 122(16):2505-11. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. PMID: 27182988.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    54. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016 05 19; 127(20):2411-5. Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, Mclntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW. PMID: 26968534; PMCID: PMC4874222.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    55. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. PMID: 26800008.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2016; 35:e314-22. Chiaretti S, Gianfelici V, O'Brien SM, Mullighan CG. PMID: 27249738.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    57. ß2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. PMID: 26588193.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    58. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. PMID: 26492205.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    59. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 Jan 21; 127(3):303-9. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. PMID: 26492934.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    60. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. PMID: 26479889.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    61. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. PMID: 26472751.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    62. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. PMID: 26308885.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    63. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015 Nov 01; 121(21):3869-76. Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. PMID: 26218678.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    64. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. PMID: 26193999.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCells
    65. VIII. Treatment of chronic lymphocytic leukaemia, where are we heading? Hematol Oncol. 2015 Jun; 33 Suppl 1:46-9. O'Brien SM. PMID: 26062054.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    66. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10):2779-86. Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD. PMID: 25726955.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCells
    67. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Oct; 171(2):281-284. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. PMID: 25824652.
      View in: PubMed   Mentions:    Fields:    
    68. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):385-91. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM. PMID: 25817936.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    69. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. PMID: 25042398.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    70. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. PMID: 24859876.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    71. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. PMID: 24705492.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    72. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13; 370(11):997-1007. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. PMID: 24450857.
      View in: PubMed   Mentions: 504     Fields:    Translation:HumansCTClinical Trials
    73. Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol Educ Book. 2014; e317-25. Brown JR, Porter DL, O'Brien SM. PMID: 24857119.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    74. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clin Adv Hematol Oncol. 2014 Jan; 12(1 Suppl 3):1-13. O'Brien SM, Furman RR, Byrd JC, Smith A. PMID: 24870382.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. Targeted agents in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Jan; 12 Suppl 3(1):9-11. O'Brien SM. PMID: 25856007.
      View in: PubMed   Mentions:    Fields:    
    76. Update on ibrutinib. Clin Adv Hematol Oncol. 2013 Nov; 11(11):735-7. O'Brien SM. PMID: 24896547.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013 Feb 10; 31(5):584-91. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. PMID: 23270003.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    78. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. PMID: 22778323.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    79. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. PMID: 21725050.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    80. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2085-93. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. PMID: 21670470.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    81. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17; 117(11):3016-24. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. PMID: 21245487; PMCID: PMC4123386.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    82. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM, CLL Research Consortium . PMID: 20806349.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    83. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. PMID: 20658954.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    84. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21. Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. PMID: 20026800.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    85. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. PMID: 18931344.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    86. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 01; 111(11):5291-7. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. PMID: 18334676; PMCID: PMC4082321.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCellsCTClinical Trials
    87. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol. 2008 Apr; 80(4):296-8. Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ. PMID: 18182081.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    88. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006 Sep; 7(2):125-30. O'Brien SM, Keating MJ, Mocarski ES. PMID: 17026823.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    89. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2006 Aug; 81(8):1105-29. Yee KW, O'Brien SM. PMID: 16901035.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    90. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. PMID: 16583431.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    91. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2):202-9. Wierda WG, O'Brien SM. PMID: 16616067.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    92. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res. 2007 Feb; 31(2):139-45. Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien SM, Verstovsek S, Armitage JO, Giles FJ. PMID: 16545870.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    93. Emerging drugs for chronic lymphocytic leukaemia. Expert Opin Emerg Drugs. 2006 Mar; 11(1):167-89. Yee KW, O'Brien SM. PMID: 16503834.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    94. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. PMID: 16497968.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    95. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. PMID: 16478631.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    96. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11. Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. PMID: 16332390.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    97. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Oct 20; 23(30):7697-702. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. PMID: 16186597.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    98. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. PMID: 16166440.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    99. Richter's syndrome: biology and therapy. Cancer J. 2005 May-Jun; 11(3):161-74. Yee KW, O'Brien SM, Giles FJ. PMID: 16053658.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    100. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. PMID: 15863204.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    101. An update on the management of chronic lymphocytic leukaemia. Expert Opin Pharmacother. 2004 Jul; 5(7):1535-54. Yee KW, O'Brien SM, Giles FJ. PMID: 15212604.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    102. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004 Jun; 28(6):595-604. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Kantarjian HM, Armitage JO, Albitar M. PMID: 15120936.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    103. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):619-39, ix. Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. PMID: 15271396.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    104. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):753-74, xii. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. PMID: 15271404.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    105. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res. 2004 Apr; 28(4):353-7. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. PMID: 15109534.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    106. Treatment of chronic lymphocytic leukemia. Semin Oncol. 2004 Apr; 31(2 Suppl 4):60-5. Ferrajoli A, O'Brien SM. PMID: 15124136.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004 Mar 15; 100(6):1179-85. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. PMID: 15022284.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    108. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. PMID: 14669286.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    109. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003 Dec; 123(5):850-7. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Keating MJ, Kantarjian HM, Armitage JO, Albitar M. PMID: 14632776.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    110. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. PMID: 12921945.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    111. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003 Oct; 44(10):1719-25. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. PMID: 14692524.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    112. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. PMID: 12910522.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    113. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep; 52(3):223-8. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM. PMID: 12783199.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    114. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. PMID: 12783207.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    115. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. PMID: 12655528.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    116. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. PMID: 12649163.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    117. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. PMID: 12637470.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    118. Update: chronic myelogenous leukemia clinical practice guidelines. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S29-40. O'Brien SM, Kantarjian H, Radich J. PMID: 19795574.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    119. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003 Apr 01; 101(7):2507-13. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. PMID: 12446458.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    120. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. PMID: 12153163.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    121. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 2002 Feb 01; 20(3):656-64. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. PMID: 11821445.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    Susan's Networks
    Concepts (374)
    Derived automatically from this person's publications.
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _